|
Market Closed -
Nasdaq
16:00:00 2026-09-09 EDT
|
5-day change | 1st Jan Change | ||
| 145.09 USD | -0.58% |
|
-0.68% | +66.12% |
Company Valuation: Protagonist Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,632 | 536.8 | 1,323 | 2,300 | 5,460 | 9,389 | - | - |
| Change | - | -67.12% | 146.4% | 73.94% | 137.35% | 71.95% | - | - |
| Enterprise Value (EV) 1 | 1,305 | 411 | 1,136 | 2,203 | 5,332 | 8,850 | 8,877 | 8,817 |
| Change | - | -68.51% | 176.35% | 93.98% | 142% | 65.99% | 0.31% | -0.68% |
| P/E | -12.6x | -4.2x | -16.5x | 9.13x | -42.6x | 31.2x | -306x | 82.6x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 1.03x | 0.4x | -0x | 0x | -0x | 3x | -0x |
| Capitalization / Revenue | 59.7x | 20.2x | 22x | 5.3x | 119x | 17.3x | 46.2x | 26.2x |
| EV / Revenue | 47.7x | 15.5x | 18.9x | 5.07x | 116x | 16.3x | 43.6x | 24.6x |
| EV / EBITDA | -10.4x | - | -12.3x | 8.69x | -34x | 29.8x | -102x | 76.7x |
| EV / EBIT | -10.4x | -3.13x | -12.1x | 8.71x | -33.7x | 29.1x | -145x | 88.6x |
| EV / FCF | -12x | -3.77x | -16x | 12.1x | 95.1x | 32.9x | 58.8x | 28.7x |
| FCF Yield | -8.35% | -26.5% | -6.24% | 8.3% | 1.05% | 3.04% | 1.7% | 3.48% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.71 | -2.6 | -1.39 | 4.23 | -2.05 | 4.651 | -0.4742 | 1.756 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 27.36 | 26.58 | 60 | 434.4 | 46.02 | 542.3 | 203.4 | 358.9 |
| EBITDA 1 | -125 | - | -92.68 | 253.7 | -156.8 | 297.2 | -87.13 | 115 |
| EBIT 1 | -125.8 | -131.4 | -93.65 | 252.8 | -158.1 | 304.2 | -61.35 | 99.51 |
| Net income 1 | -125.6 | -127.4 | -78.96 | 275.2 | -130.1 | 323.8 | -32.12 | 131.2 |
| Net Debt 1 | -326.9 | -125.7 | -186.7 | -97.25 | -128.4 | -538.2 | -511.1 | -571.3 |
| Reference price 2 | 34.20 | 10.91 | 22.93 | 38.60 | 87.34 | 145.09 | 145.09 | 145.09 |
| Nbr of stocks (in thousands) | 47,728 | 49,198 | 57,678 | 59,598 | 62,516 | 64,708 | - | - |
| Announcement Date | 2/28/22 | 3/15/23 | 2/27/24 | 2/21/25 | 2/25/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 31.2x | 16.32x | 29.78x | -.--% | 9.39B | |
| 31.44x | 5.66x | 16.96x | 1.03% | 46.38B | |
| -21.25x | 245.77x | -22.82x | -.--% | 44.51B | |
| 33.09x | 3.22x | 13.91x | -.--% | 42.3B | |
| 45.98x | 5.31x | 29.05x | -.--% | 39.91B | |
| 27.78x | 8.36x | 21.2x | 0.41% | 32.79B | |
| 33.34x | 5.46x | 24.79x | -.--% | 16.36B | |
| 23.65x | 2.07x | 8.96x | 1.13% | 14.31B | |
| 74.46x | 3.94x | 15.27x | -.--% | 13.29B | |
| Average | 31.08x | 32.90x | 15.23x | 0.29% | 28.8B | |
| Weighted average by Cap. | 26.32x | 46.87x | 12.46x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- PTGX Stock
- Valuation Protagonist Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
